Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis

doi:10.12114/j.issn.1007-9572.2025.0289

Chinese General Practice ›› 2026, Vol. 29 ›› Issue (24): 3509-3519.DOI: 10.12114/j.issn.1007-9572.2025.0289

Special Issue: 心力衰竭最新文章合辑；心血管最新文章合辑

• Article·Study of Evidence-based Medicine • Previous Articles Next Articles

Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis

1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2. Geriatric Cardiovascular Department, the First Hospital of Lanzhou University, Lanzhou 730000, China
3. Geriatric Cardiovascular Department and Gansu Clinical Research Center for Geriatric Disease, the First Hospital of Lanzhou University, Lanzhou 730000, China

Received:2025-09-03 Revised:2025-10-30 Published:2026-08-20 Online:2026-07-03
Contact: LIU Yongming

司美格鲁肽治疗心力衰竭疗效和安全性的Meta分析

1．730000　甘肃省兰州市，兰州大学第一临床医学院
2．730000　甘肃省兰州市，兰州大学第一医院老年心血管病科
3．730000　甘肃省兰州市，甘肃省老年疾病临床医学研究中心

通讯作者: 刘永铭
作者简介:
作者贡献：
李雪妮负责研究的构思、设计、文献检索策略的制订、文献筛选、数据收集、研究的偏倚风险评估和文章撰写；刘格婧负责文献检索策略的制订、文献筛选、数据收集和研究的偏倚风险评估；刘永铭负责文章的质量控制，解决研究过程中的分歧，对文章整体负责，监督管理。
本文为中文翻译版本，原文Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-analysis发表于Precision Medication，已获得授权。翻译与出版遵循COPE和ICMJE关于二次发表的指南。
基金资助:
甘肃省科技计划项目（重点研发计划）(20YF8FA079); 2023年兰州市科技发展指导性计划项目(2023-ZD-96)

Abstract

Abstract:

Background

The multi-target effects of semaglutide make it a breakthrough therapy for managing diabetes and obesity, offering comprehensive benefits particularly for patients with cardiovascular disease. However, its clinical applications for patients with heart failure (HF) are still under active investigation.

Objective

To systematically review the efficacy and safety of subcutaneous semaglutide in the treatment of HF regardless of the presence of obesity or type 2 diabetes (T2DM).

Methods

We searched Cochrane Library, PubMed, Embase, CNKI, Wanfang Data and VIP database from inception to November 2, 2024 for randomized controlled trials about subcutaneous semaglutide in the treatment of HF, where the experimental group received subcutaneous semaglutide and the control group received placebo. Data on HF hospitalization rate, cardiovascular death rate, all-cause death rate, serious adverse events, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and 6-minute walk distance (6-MWD) were collected and analyzed by two investigators who independently screened the literature, extracted the data, and evaluated the risk of bias of the included studies. Subgroup analyses were performed based on comorbidities and different dosages, and data were statistically analyzed using Review Manager 5.3 software.

Results

A total of 4 randomized controlled studies, with a total of 6 109 patients (3 070 in the experimental group and 3 039 in the control group). Meta-analysis results showed that compared with placebo, subcutaneous semaglutide reduced the risk of cardiovascular death (RR=0.75, 95%CI=0.61-0.92, P=0.005), all-cause death (RR=0.81, 95%CI=0.67-0.98, P=0.03) and serious adverse events (RR=0.53, 95%CI=0.41-0.68, P<0.000 01). Subgroup analysis found that subcutaneous semaglutide could increase KCCQ-CSS (MD=7.58, 95%CI=4.40-10.77, P<0.000 01) and 6-MWD (MD=16.91, 95%CI=8.98-24.83, P<0.000 1) and reduced the risk of HF hospitalization (RR=0.41, 95%CI=0.26-0.65, P=0.000 1) of patients in HF with preserved ejection fraction (HFpEF) with obesity. In patients without T2DM, semaglutide was superior to placebo in reducing the risk of HF hospitalization (RR=0.16, 95%CI=0.04-0.68, P=0.01) and cardiovascular death (RR=0.76, 95%CI=0.60-0.97, P=0.03); similarly, in patients with a weekly dose of 2.4 mg, semaglutide reduced the risk of HF hospitalization (RR=0.29, 95%CI=0.14-0.58, P=0.000 5) and cardiovascular death (RR=0.75, 95%CI=0.59-0.95, P=0.02) compared with placebo, but the efficacy of the weekly dose of 1.0 mg was not significant compared with placebo.

Conclusion

Current evidence shows that subcutaneous semaglutide can reduce the risk of cardiovascular death, all-cause death and serious adverse events of heart failure patients while improving quality of life and activity tolerance and reducing risk of HF hospitalization in patients with HFpEF and obesity. Due to limited quantity and populations of the included studies, more high-quality studies are needed to verify the above conclusion.

Key words: Heart failure, Semaglutide, Efficacy, Safety, Meta-analysis

摘要：

背景

司美格鲁肽的多靶点作用使其成为糖尿病和肥胖管理的突破性药物，尤其是对合并心血管疾病的患者具有综合获益，但其对于心力衰竭（HF）患者的疗效和安全性应用仍在探索中。

目的

系统评价皮下注射司美格鲁治疗HF的疗效和安全性，不管是否肥胖或存在2型糖尿病（T2DM）。

方法

计算机检索Cochrane Library、PubMed、Embase、中国知网、万方数据知识服务平台和维普网，检索时限自建库至2024-11-02。筛选皮下注射司美格鲁肽治疗HF的随机对照试验，其中试验组为皮下注射司美格鲁肽，对照组为安慰剂。由两名研究者独立筛选、数据提取并评价纳入研究的偏倚风险，对因HF再入院、心血管死亡和全因死亡发生率、严重不良事件、堪萨斯城心肌病调查问卷评分（KCCQ-CSS）和6分钟步行距离（6-MWD）等数据收集和分析。基于合并症和不同给药剂量进行亚组分析，使用Review Manager 5.3软件进行Meta分析。

结果

共纳入4项随机对照试验，总计6 109例患者，其中试验组3 070例、对照组3 039例。Meta分析结果表明：与安慰剂相比，皮下注射司美格鲁肽可降低心血管死亡（RR=0.75，95%CI=0.61~0.92，P=0.005）、全因死亡（RR=0.81，95%CI=0.67~0.98，P=0.03）和严重不良事件（RR=0.53，95%CI=0.41~0.68，P<0.000 01）风险；亚组分析发现，皮下注射司美格鲁肽增加肥胖的射血分数保留的HF（HFpEF）患者KCCQ-CSS（MD=7.58，95%CI=4.40~10.77，P<0.000 01）和6-MWD（MD=16.91，95%CI=8.98~24.83，P<0.000 1），降低因HF再入院风险（RR=0.41，95%CI=0.26~0.65，P=0.000 1）；在不合并T2DM的患者中，司美格鲁肽在降低因HF再入院（RR=0.16，95%CI=0.04~0.68，P=0.01）和心血管死亡（RR=0.76，95%CI=0.60~0.97，P=0.03）风险方面优于安慰剂；同样，在2.4 mg/周剂量组的患者中，与安慰剂相比，皮下注射司美格鲁肽可降低因HF再入院（RR=0.29，95%CI=0.14~0.58，P=0.000 5）和心血管死亡（RR=0.75，95%CI=0.59~0.95，P=0.02）风险，但1.0 mg/周剂量组的疗效与安慰剂相比并不显著。

结论

皮下注射司美格鲁肽可安全、有效地降低HF患者的心血管死亡、全因死亡和严重不良事件发生风险，改善肥胖的HFpEF患者的生活质量和运动耐量，降低因HF再入院风险。受纳入研究数量和人群限制，上述结论尚需开展更多高质量研究予以验证。

关键词: 心力衰竭, 司美格鲁肽, 有效性, 安全性, Meta分析

CLC Number:

R 541.6

LI Xueni,LIU Gejing,LIU Yongming. Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis[J]. Chinese General Practice, 2026, 29(24): 3509-3519. DOI: 10.12114/j.issn.1007-9572.2025.0289.
李雪妮,刘格婧,刘永铭. 司美格鲁肽治疗心力衰竭疗效和安全性的Meta分析[J]. 中国全科医学, 2026, 29(24): 3509-3519. DOI: 10.12114/j.issn.1007-9572.2025.0289.

Figures/Tables 12

References 44

[1]	Heidenreich P A, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145(18): e895-e1032. DOI: 10.1161/CIR.0000000000001063.
[2]	中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. DOI: 10.3760/cma.j.cn112148-20231101-00405.
[3]	Pandey A, Khan M S, Patel K V, et al. Predicting and preventing heart failure in type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2023, 11(8): 607-624. DOI: 10.1016/S2213-8587(23)00128-6.
[4]	Butt J H, Petrie M C, Jhund P S, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox[J]. Eur Heart J, 2023, 44(13): 1136-1153. DOI: 10.1093/eurheartj/ehad083.
[5]	Zhao X, Wang M H, Wen Z T, et al. GLP-1 receptor agonists: beyond their pancreatic effects[J]. Front Endocrinol (Lausanne), 2021, 12: 721135. DOI: 10.3389/fendo.2021.721135.
[6]	Yang X D, Yang Y Y. Clinical pharmacokinetics of semaglutide: a systematic review[J]. Drug Des Devel Ther, 2024, 18: 2555-2570. DOI: 10.2147/DDDT.S470826.
[7]	Moiz A, Filion K B, Tsoukas M A, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation[J]. Am J Med, 2025, 138(6): 934-940. DOI: 10.1016/j.amjmed.2025.01.021.
[8]	Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes[J]. Diabetes Ther, 2019, 10(1): 5-19. DOI: 10.1007/s13300-018-0535-9.
[9]	Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management[J]. J Investig Med, 2022, 70(1): 5-13. DOI: 10.1136/jim-2021-001952.
[10]	Marso S P, Bain S C, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844. DOI: 10.1056/NEJMoa1607141.
[11]	Kosiborod M N, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials[J]. Lancet, 2024, 404(10456): 949-961. DOI: 10.1016/S0140-6736(24)01643-X.
[12]	Page M J, Mckenzie J E, Bossuyt P M, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J]. BMJ, 2021, 372: n71. DOI: 10.1136/bmj.n71.
[13]	Pratley R E, Tuttle K R, Rossing P, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial[J]. J Am Coll Cardiol, 2024, 84(17): 1615-1628. DOI: 10.1016/j.jacc.2024.08.004.
[14]	Kosiborod M N, Petrie M C, Borlaug B A, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes[J]. N Engl J Med, 2024, 390(15): 1394-1407. DOI: 10.1056/NEJMoa2313917.
[15]	Kosiborod M N, Abildstrøm S Z, Borlaug B A, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2023, 389(12): 1069-1084. DOI: 10.1056/NEJMoa2306963.
[16]	Deanfield J, Verma S, Scirica B M, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial[J]. Lancet, 2024, 404(10454): 773-786. DOI: 10.1016/S0140-6736(24)01498-3.
[17]	Lincoff A M, Brown-Frandsen K, Colhoun H M, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med, 2023, 389(24): 2221-2232. DOI: 10.1056/NEJMoa2307563.
[18]	Perkovic V, Tuttle K R, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391(2): 109-121. DOI: 10.1056/NEJMoa2403347.
[19]	Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial[J]. Eur J Heart Fail, 2017, 19(1): 69-77. DOI: 10.1002/ejhf.657.
[20]	Margulies K B, Hernandez A F, Redfield M M, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2016, 316(5): 500-508. DOI: 10.1001/jama.2016.10260.
[21]	Liu Q K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists[J]. Front Endocrinol (Lausanne), 2024, 15: 1431292. DOI: 10.3389/fendo.2024.1431292.
[22]	Husain M, Bain S C, Jeppesen O K, et al. Semaglutide(SUSTAIN and PIONEER)reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk[J]. Diabetes Obes Metab, 2020, 22(3): 442-451. DOI: 10.1111/dom.13955.
[23]	Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials[J]. Trends Endocrinol Metab, 2019, 30(9): 578-589. DOI: 10.1016/j.tem.2019.07.004.
[24]	Yue L, Chen S C, Ren Q J, et al. Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice[J]. Front Endocrinol (Lausanne), 2022, 13: 995007. DOI: 10.3389/fendo.2022.995007.
[25]	He W X, Wei J H, Liu X, et al. Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome[J]. Sci Rep, 2024, 14(1): 11824. DOI: 10.1038/s41598-024-62465-6.
[26]	García-Vega D, Sánchez-López D, Rodríguez-Carnero G, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network[J]. Cardiovasc Diabetol, 2024, 23(1): 1. DOI: 10.1186/s12933-023-02096-9.
[27]	Butler J, Shah S J, Petrie M C, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials[J]. Lancet, 2024, 403(10437): 1635-1648. DOI: 10.1016/S0140-6736(24)00469-0.
[28]	Rodríguez Jiménez B, Rodríguez De Vera Gómez P, Belmonte Lomas S, et al. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2024, 15: 1386542. DOI: 10.3389/fendo.2024.1386542.
[29]	Solomon S D, Ostrominski J W, Wang X W, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure[J]. J Am Coll Cardiol, 2024, 84(17): 1587-1602. DOI: 10.1016/j.jacc.2024.08.021.
[30]	Nielsen J, Narayan K V, Cunningham S A. Incidence of obesity across adulthood in the United States, 2001-2017-a national prospective analysis[J]. Am J Clin Nutr, 2023, 117(1): 141-148. DOI: 10.1016/j.ajcnut.2022.10.012.
[31]	Nanda M, Sharma R, Mubarik S, et al. Type-2 diabetes mellitus(T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions[J]. Endocrine, 2022, 77(3): 444-454. DOI: 10.1007/s12020-022-03125-5.
[32]	Dong B Q, Zhao Y T, Wang J L, et al. Epidemiological analysis of chronic kidney disease from 1990 to 2019 and predictions to 2030 by Bayesian age-period-cohort analysis[J]. Ren Fail, 2024, 46(2): 2403645. DOI: 10.1080/0886022X.2024.2403645.
[33]	Dejesus R S, Croghan I T, Jacobson D J, et al. Incidence of obesity at 1 and 3 years among community dwelling adults: a population-based study[J]. J Prim Care Community Health, 2022, 13: 21501319211068632. DOI: 10.1177/21501319211068632.
[34]	Gerhardt T, Gerhardt L M S, Ouwerkerk W, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study[J]. Lancet Glob Health, 2023, 11(12): e1874-e1884. DOI: 10.1016/S2214-109X(23)00408-4.
[35]	Elgendy I Y, Pepine C J. Heart failure with preserved ejection fraction: is ischemia due to coronary microvascular dysfunction a mechanistic factor?[J]. Am J Med, 2019, 132(6): 692-697. DOI: 10.1016/j.amjmed.2018.12.038.
[36]	Savji N, Meijers W C, Bartz T M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF[J]. JACC Heart Fail, 2018, 6(8): 701-709. DOI: 10.1016/j.jchf.2018.05.018.
[37]	Kapitza C, Dahl K, Jacobsen J B, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial[J]. Diabetologia, 2017, 60(8): 1390-1399. DOI: 10.1007/s00125-017-4289-0.
[38]	Liu Y P, Ruan B Y, Jiang H N, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials[J]. Am J Clin Nutr, 2023, 118(3): 614-626. DOI: 10.1016/j.ajcnut.2023.04.017.
[39]	中华医学会糖尿病学分会, 朱大龙, 郭立新. 中国糖尿病防治指南(2024版)[J]. 中华糖尿病杂志, 2025(1): 16-139.
[40]	Kristensen S L, Rørth R, Jhund P S, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785. DOI: 10.1016/S2213-8587(19)30249-9.
[41]	苏晞, 吴明祥. 射血分数降低的心力衰竭的疾病管理与药物治疗优化[J]. 中国心血管杂志, 2023, 28(3): 277-281.
[42]	葛均波, 霍勇, 杨杰孚, 等. 慢性心力衰竭"新四联"药物治疗临床决策路径专家共识[J]. 中国循环杂志, 2022, 37(8): 769-781.
[43]	Toth P P, Gauthier D. Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches[J]. Postgrad Med, 2021, 133(2): 125-139. DOI: 10.1080/00325481.2020.1842620.
[44]	Borlaug B A, Sharma K, Shah S J, et al. Heart failure with preserved ejection fraction JACC scientific statement[J]. J Am Coll Cardiol, 2023, 81(18): 1810-1834. DOI: 10.1016/j.jacc.2023.01.049.

步骤	检索式
#1	(heart failure[MeSH Terms]) OR ( "Cardiac Failure" [Title/Abstract] OR "Heart Decompensation" [Title/Abstract] OR "Decompensation Heart" [Title/Abstract] OR "Congestive Heart Failure" [Title/Abstract] OR "Heart Failure, Congestive" [Title/Abstract] OR "Heart Failure, Right-Sided" [Title/Abstract] OR "Heart Failure, Right Sided" [Title/Abstract] OR "Right-Sided Heart Failure" [Title/Abstract] OR "Right Sided Heart Failure" [Title/Abstract] OR "Heart Failure, Left-Sided" [Title/Abstract] OR "Heart Failure, Left Sided" [Title/Abstract] OR "Left-Sided Heart Failure" [Title/Abstract] OR "Left Sided Heart Failure" [Title/Abstract] OR "Myocardial Failure" [Title/Abstract] OR "Heart Failure, Diastolic" [Title/Abstract] OR "Heart Failure, Systolic" [Title/Abstract] OR "Heart Diseases" [Title/Abstract])
#2	Semaglutide[Title/Abstract] OR Ozempic[Title/Abstract] OR Rybelsus[Title/Abstract] OR Wegovy[Title/Abstract]
#3	#1 AND #2

步骤	检索式
#1	(heart failure[MeSH Terms]) OR ( "Cardiac Failure" [Title/Abstract] OR "Heart Decompensation" [Title/Abstract] OR "Decompensation Heart" [Title/Abstract] OR "Congestive Heart Failure" [Title/Abstract] OR "Heart Failure, Congestive" [Title/Abstract] OR "Heart Failure, Right-Sided" [Title/Abstract] OR "Heart Failure, Right Sided" [Title/Abstract] OR "Right-Sided Heart Failure" [Title/Abstract] OR "Right Sided Heart Failure" [Title/Abstract] OR "Heart Failure, Left-Sided" [Title/Abstract] OR "Heart Failure, Left Sided" [Title/Abstract] OR "Left-Sided Heart Failure" [Title/Abstract] OR "Left Sided Heart Failure" [Title/Abstract] OR "Myocardial Failure" [Title/Abstract] OR "Heart Failure, Diastolic" [Title/Abstract] OR "Heart Failure, Systolic" [Title/Abstract] OR "Heart Diseases" [Title/Abstract])
#2	Semaglutide[Title/Abstract] OR Ozempic[Title/Abstract] OR Rybelsus[Title/Abstract] OR Wegovy[Title/Abstract]
#3	#1 AND #2

第一作者	发表时间（年）	原始研究名称	临床试验注册号	试验阶段	治疗方案（T/C）	样本量（T/C）	年龄（T/C）（岁）	女性（T/C）[例（%）]	BMI（T/C）（kg/m²）	LVEF（T/C）（%）	人群特征	随访时间	结局指标
Pratley^[13]	2024	FLOW	NCT03819153	Ⅲ	司美格鲁肽（1.0 mg/周）/安慰剂	342/336	68（63~73）	247（36.7）	33.3（28.9~38.0）	NA	HF+T2DM+CKD	3.4年	①②
Kosiborod^[14]	2024	STEP-HFpEF DM	NCT04916470	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	310/306	69（62~74）/70（63~75）	128（41.3）/145（47.4）	36.9（33.6~41.5）/36.9（33.5~41.1）	57（50~61）/55（50~60）	HFpEF+肥胖+T2DM	52周	①②③④
Kosiborod^[15]	2023	STEP-HFpEF	NCT04788511	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	263/266	70（62~75）/69（62~75）	149（56.7）/148（55.6）	37.2（33.9~41.1）/36.9（33.3~41.6）	57（50~60）/57（50~60）	HFpEF+肥胖	52周	①②③④
Deanfield^[16]	2024	SELECT	NCT03574597	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	2 155/2 131	61.9±8.7	1 183（26.6）	33.9±5.3	NA	HF+超重（或肥胖）	104周	②③

第一作者	发表时间（年）	原始研究名称	临床试验注册号	试验阶段	治疗方案（T/C）	样本量（T/C）	年龄（T/C）（岁）	女性（T/C）[例（%）]	BMI（T/C）（kg/m²）	LVEF（T/C）（%）	人群特征	随访时间	结局指标
Pratley^[13]	2024	FLOW	NCT03819153	Ⅲ	司美格鲁肽（1.0 mg/周）/安慰剂	342/336	68（63~73）	247（36.7）	33.3（28.9~38.0）	NA	HF+T2DM+CKD	3.4年	①②
Kosiborod^[14]	2024	STEP-HFpEF DM	NCT04916470	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	310/306	69（62~74）/70（63~75）	128（41.3）/145（47.4）	36.9（33.6~41.5）/36.9（33.5~41.1）	57（50~61）/55（50~60）	HFpEF+肥胖+T2DM	52周	①②③④
Kosiborod^[15]	2023	STEP-HFpEF	NCT04788511	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	263/266	70（62~75）/69（62~75）	149（56.7）/148（55.6）	37.2（33.9~41.1）/36.9（33.3~41.6）	57（50~60）/57（50~60）	HFpEF+肥胖	52周	①②③④
Deanfield^[16]	2024	SELECT	NCT03574597	Ⅲ	司美格鲁肽（2.4 mg/周）/安慰剂	2 155/2 131	61.9±8.7	1 183（26.6）	33.9±5.3	NA	HF+超重（或肥胖）	104周	②③

亚组分类	分析类型	纳入研究数	因HF再入院		心血管死亡		全因死亡
亚组分类	分析类型	纳入研究数	效应量（95%CI）	基准化权重	效应量（95%CI）	基准化权重	效应量（95%CI）	基准化权重
HFpEF	主分析	3	0.41（0.26~0.65）	100.00%	0.80（0.54~1.21）	100.00%	0.80（0.59~1.09）	100.00%
	剔除后	2	0.28（0.14~0.55）	65.40%	0.27（0.04~1.64）	11.10%	0.64（0.28~1.46）	15.90%
肥胖	主分析	3	—	—	0.75（0.59~0.95）	100.00%	0.81（0.67~0.98）	100.00%
	剔除后	2	—	—	0.27（0.04~1.64）	3.80%	0.64（0.28~1.46）	6.60%
2.4 mg	主分析	3	—	—	0.75（0.59~0.95）	100.00%	—	—
	剔除后	2	—	—	0.27（0.04~1.64）	3.83%	—	—
合并T2DM	主分析	2	0.57（0.25~1.32）	100.00%	0.71（0.49~1.03）	100.00%	—	—
	剔除后	1	0.34（0.16~0.76）	43.87%	0.25（0.03~2.20）	6.92%	—	—
不合并T2DM	主分析	2	—	—	0.76（0.60~0.97）	100.00%	0.82（0.68~1.00）	100.00%
	剔除后	1	—	—	0.34（0.01~8.24）	1.13%	0.76（0.17~3.36）	1.99%

Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis

司美格鲁肽治疗心力衰竭疗效和安全性的Meta分析

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 12

References 44

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	GUO Zhihong, CHEN Yingying, LIU Dewu. Efficacy and Safety of Antibiotic Bone Cement Combined with Vacuum Sealing Drainage for Diabetic Foot: a Meta-analysis [J]. Chinese General Practice, 2026, 29(30): 4503-4512.
[2]	YAO Ying, DUAN Liran, HAN Dianli, MIAO Tianxin, CHEN Ke, ZHANG Lan, GU Haiyue. Construction and Application of Fall Prevention Continuous Intervention Program for Young-old Patients [J]. Chinese General Practice, 2026, 29(30): 4415-4423.
[3]	ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336.
[4]	JIANG Yanlin, WANG Zhe, ZHAI Rui, ZHANG Mengjie, CHEN Xi, WANG Junhong. Screening Optimal Traditional Chinese Medicine Compound Formulas for ADHD Treatment: a Study Integrating Network Meta-analysis and Entropy-weighted TOPSIS Method [J]. Chinese General Practice, 2026, 29(27): 3985-3994.
[5]	DU Ruofang, CAO Yang, LIU Dianna, ZHANG Qixin, WANG Xiaofan, SHI Enze, ZHANG Yuxin, LI Quanwang. A 10-Year Clinical Review of Raw Pinelliae Rhizoma in Tumor Treatment: Usage Patterns and Safety Evaluation [J]. Chinese General Practice, 2026, 29(27): 3995-4003.
[6]	GUO Junchi, ZHANG Mingyan, QIN Guangning, XU Qiang, LU Meijuan. Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution [J]. Chinese General Practice, 2026, 29(27): 3924-3930.
[7]	WANG Wei, YU Fei, YAN Xiaohong. Application and Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure with Different Etiologies: Evidence from Ischemic and Non-ischemic Heart Failure [J]. Chinese General Practice, 2026, 29(27): 3976-3984.
[8]	ZHUANG Mingnan, YAN Henghao, XIAO Ningkun, YIN Mingyue, FAN Zhiwei, LIU Chaohui, ZOU Xintong, ZHOU Yuehua, BI Zhiyuan, DENG Hengzhi, WU Bitai, SONG Zhiquan, SHI Donglin. Effects of Interval and Continuous Training on Cognitive Function in Healthy Adults: a Systematic Review and Three-level Meta-analysis [J]. Chinese General Practice, 2026, 29(26): 3816-3828.
[9]	CHEN Jingjing, BAI Xinyuan, SHA Huizi, SUN Yi, NI Jiayao, TONG Fan, ZOU Lu, MENG Fanyan, DU Juan. Analysis of the Efficacy and Safety of Gemcitabine plus S-1 Regimen versus S-1 Combined with Oxaliplatin and Irinotecan Regimen as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma [J]. Chinese General Practice, 2026, 29(26): 3767-3773.
[10]	ZHAO Yiru, HAO Xinyu, ZHAO Lei, ZHANG Caihui, WANG Zhaoxia, ZHANG Yueying. Summary of the Best Evidence for the Management of Diuretic Resistance in Patients with Heart Failure [J]. Chinese General Practice, 2026, 29(25): 3694-3703.
[11]	SI Xinying, MA Wenyuan, GUO Zhixun, QI Shuo, CHEN Xiaoheng, LI Zhe, LI Lu, DING Zhiguo. Preliminary Development of a Syndrome Efficacy Evaluation Scale for Hypothyroidism Secondary to Hashimoto's Thyroiditis: Based on Expert Consultation and Clinical Investigation [J]. Chinese General Practice, 2026, 29(24): 3528-3537.
[12]	WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508.
[13]	PEI Ruqing, ZHOU Yuqiu, ZHANG Siyu, LIU Xijun. Meta-analysis of Influencing Factors of Relapse in Chinese Patients with Schizophrenia [J]. Chinese General Practice, 2026, 29(23): 3359-3370.
[14]	LI Yutong, ZHAO Danting, JIANG Feng, WANG Yanna, LIU Yizong, LIANG Wenjuan, LU Jiahai. Systematic Review and Meta-analysis of the Efficacy and Safety of mRNA and Recombinant Protein Subunit Vaccines Against Respiratory Syncytial Virus [J]. Chinese General Practice, 2026, 29(19): 2744-2752.
[15]	ZHANG Wenbo, WANG Junlong, ZHANG Yuping, JIANG Shuai, WANG Huaqi. The Risk of Pre-COPD Populations Progressing to COPD under Different Criteria: a Meta-analysis [J]. Chinese General Practice, 2026, 29(19): 2735-2743.